Carmen Viada
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Carmen Viada has a total of 166 co-authors. Here are the top co-authors by number of shared publications:
- Martha Fors
One Health Research Group, Facultad de Ciencias de la Salud, Universidad de Las Américas, Quito 170125, Ecuador
10 shared publications - Tania Crombet
Center of Molecular Immunology, Havana, Cuba
8 shared publications - Elia Neninger Vinageras
Clinical Oncology Department, University Hospital “Hermanos Ameijeiras”, Havana 10400, Cuba
5 shared publications - Mayra Ramos-Suzarte
Center of Molecular Immunology, Havana, Cuba
5 shared publications - Patricia Lorenzo-Luaces
CIM: Centro de Inmunologia Molecular
4 shared publications - Agustin Lage
Clinical Research Division, Center of Molecular Immunology, Calle 216 esq 15. Atabey, 11600, Havana, Cuba
3 shared publications
Latest Publications
- 1 February 2026
- Published by Springer Nature
- p. 685-696
Platform for the Integration and Analysis of Clinical Data at the Center of Molecular Immunology
- 1 February 2026
- Published by Springer Nature
- p. 685-696
Platform for the Integration and Analysis of Clinical Data at the Center of Molecular Immunology
- Open Access
Real-World Effectiveness of Racotumomab as Maintenance Therapy in Advanced Non-Small Cell Lung Cancer Patients
Background: Advanced non-small cell lung cancer (NSCLC) has limited curative options and poor survival. Racotumomab, an anti-idiotype monoclonal antibody vaccine targeting tumor gangliosides, has shown efficacy in clinical trials. This study evaluated its real-world effectiveness as maintenance therapy following first-line chemotherapy. Materials and Methods: A multi-center observational study was conducted on 162 patients with advanced NSCLC who received racotumomab from 2012 to 2024. Effectiveness was evaluated in the intention-to-treat (ITT) cohort. Overall survival (OS) was estimated, with subgroup analyses conducted according to clinical and demographic factors. Results: The median OS was 14.9 months (95% CI: 11.7–18.1), and the 5-year survival rate reached 20%. Patients diagnosed with stage III disease, those with better Eastern Cooperative Oncology Group (ECOG) performance status, and individuals younger than 65 years experienced significantly longer survival. Racotumomab demonstrated a favorable hazard ratio compared to historical controls (HR 0.44 vs. supportive care; HR 0.55 vs. docetaxel). Conclusions: In the era of immune checkpoint inhibitors, these real-world results indicate a promising role for racotumomab in the maintenance setting for advanced NSCLC. These findings provide a strong rationale for further investigation of racotumomab in the context of modern immunotherapy, particularly in combination trials with other immunomodulatory antibodies, along with the validation of clinical and biologic predictive biomarkers.
Open AccessReal-World Effectiveness of Racotumomab as Maintenance Therapy in Advanced Non-Small Cell Lung Cancer Patients
Background: Advanced non-small cell lung cancer (NSCLC) has limited curative options and poor survival. Racotumomab, an anti-idiotype monoclonal antibody vaccine targeting tumor gangliosides, has shown efficacy in clinical trials. This study evaluated its real-world effectiveness as maintenance therapy following first-line chemotherapy. Materials and Methods: A multi-center observational study was conducted on 162 patients with advanced NSCLC who received racotumomab from 2012 to 2024. Effectiveness was evaluated in the intention-to-treat (ITT) cohort. Overall survival (OS) was estimated, with subgroup analyses conducted according to clinical and demographic factors. Results: The median OS was 14.9 months (95% CI: 11.7–18.1), and the 5-year survival rate reached 20%. Patients diagnosed with stage III disease, those with better Eastern Cooperative Oncology Group (ECOG) performance status, and individuals younger than 65 years experienced significantly longer survival. Racotumomab demonstrated a favorable hazard ratio compared to historical controls (HR 0.44 vs. supportive care; HR 0.55 vs. docetaxel). Conclusions: In the era of immune checkpoint inhibitors, these real-world results indicate a promising role for racotumomab in the maintenance setting for advanced NSCLC. These findings provide a strong rationale for further investigation of racotumomab in the context of modern immunotherapy, particularly in combination trials with other immunomodulatory antibodies, along with the validation of clinical and biologic predictive biomarkers.
- Open Access
- 15 September 2025
- Published by Clinical Biotec S.L. in Bionatura Journal
- Vol. 2 (3) , 16
Post-reactivation humoral immune response with Soberana 01 vaccine in IPK workers, 2022.
SARS-CoV-2, the causative agent of COVID-19, was declared a pandemic on March 11, 2020, and due to its high morbidity and mortality rates, it became a global health priority. Cuba developed its vaccines (SOBERANA 01, 02, and Plus), and as part of an intervention study launched in 2021 among healthcare workers, a booster dose was administered in November of that year. This study aimed to evaluate the humoral immune response after the SOBERANA 01 booster in workers at the Pedro Kourí Institute of Tropical Medicine (IPK) and to analyze its association with sociodemographic and clinical-epidemiological variables. A total of 418 whole blood and serum samples were collected one month after the booster, and anti-SARS- CoV-2 antibodies were assessed using a lateral flow immunochromatographic assay and the UMELISA SARS-CoV-2 IgG technique. The rapid assay detected IgG in 95.7% of samples and marginal IgM positivity (0.23%), while UMELISA confirmed IgG in 99.5% of cases. No significant differences were observed according to sociodemographic or clinical characteristics, although a positive association was found between prior COVID-19 infection and rapid test positivity. These findings demonstrate that SOBERANA 01 induces a strong humoral response in healthcare workers, supporting its use in high-risk populations and confirming that Cuban-developed vaccines provide immune protection comparable to internationally recognized platforms.
- 15 September 2025
- Published by Clinical Biotec S.L. in Bionatura Journal
- Vol. 2 (3) , 16
Open AccessPost-reactivation humoral immune response with Soberana 01 vaccine in IPK workers, 2022.
SARS-CoV-2, the causative agent of COVID-19, was declared a pandemic on March 11, 2020, and due to its high morbidity and mortality rates, it became a global health priority. Cuba developed its vaccines (SOBERANA 01, 02, and Plus), and as part of an intervention study launched in 2021 among healthcare workers, a booster dose was administered in November of that year. This study aimed to evaluate the humoral immune response after the SOBERANA 01 booster in workers at the Pedro Kourí Institute of Tropical Medicine (IPK) and to analyze its association with sociodemographic and clinical-epidemiological variables. A total of 418 whole blood and serum samples were collected one month after the booster, and anti-SARS- CoV-2 antibodies were assessed using a lateral flow immunochromatographic assay and the UMELISA SARS-CoV-2 IgG technique. The rapid assay detected IgG in 95.7% of samples and marginal IgM positivity (0.23%), while UMELISA confirmed IgG in 99.5% of cases. No significant differences were observed according to sociodemographic or clinical characteristics, although a positive association was found between prior COVID-19 infection and rapid test positivity. These findings demonstrate that SOBERANA 01 induces a strong humoral response in healthcare workers, supporting its use in high-risk populations and confirming that Cuban-developed vaccines provide immune protection comparable to internationally recognized platforms.
- Open Access
- 15 June 2025
- Published by Clinical Biotec S.L. in Bionatura Journal
- Vol. 2 (2) , 14
Machine Learning-Based Survival Prediction in Cancer Patients Treated with Nimotuzumab: A Real-World Data Mining Approach
Nimotuzumab, a humanized monoclonal antibody targeting the epidermal growth factor receptor (EGFR), has demonstrated clinical benefit in various epithelial tumors. However, selecting the right patient populations remains a challenge, particularly when considering real-world treatment scenarios and diverse tumor types. This study aimed to identify clinical and demographic subgroups of patients with the highest survival benefit from Nimotuzumab, using decision tree models applied to integrated clinical trial data. A total of 1,871 patients diagnosed with head and neck, brain, and esophageal cancers were included from 19 studies (phases I to IV and observational). Survival-related variables were analyzed using decision tree algorithms, a machine learning method suited for revealing complex, non-linear patterns among clinical features. The models stratified patients based on baseline characteristics and treatment outcomes. The results revealed distinct predictive profiles for each cancer type. In head and neck cancer, survival was best predicted by race, disease status, use of radiotherapy, performance status, and toxic habits. In brain tumors, the most influential variables were age, performance status, and histological subtype. In esophageal cancer, survival was mainly determined by sex, histological diagnosis, and race. These variables consistently emerged as key decision nodes in the trained models. The novelty of this study lies in its use of a machine learning approach across multiple tumor types treated with the same targeted therapy, Nimotuzumab. It is also among the first to apply such methodology to real-world data from low- and middle-income countries. By generating interpretable decision trees, the study offers a practical tool for identifying patient subgroups that are most likely to benefit from EGFR-targeted treatment, thereby supporting more efficient, personalized cancer care. These findings reinforce the value of integrating data mining and artificial intelligence techniques into oncology to enhance treatment selection and improve patient outcomes.
- 15 June 2025
- Published by Clinical Biotec S.L. in Bionatura Journal
- Vol. 2 (2) , 14
Open AccessMachine Learning-Based Survival Prediction in Cancer Patients Treated with Nimotuzumab: A Real-World Data Mining Approach
Nimotuzumab, a humanized monoclonal antibody targeting the epidermal growth factor receptor (EGFR), has demonstrated clinical benefit in various epithelial tumors. However, selecting the right patient populations remains a challenge, particularly when considering real-world treatment scenarios and diverse tumor types. This study aimed to identify clinical and demographic subgroups of patients with the highest survival benefit from Nimotuzumab, using decision tree models applied to integrated clinical trial data. A total of 1,871 patients diagnosed with head and neck, brain, and esophageal cancers were included from 19 studies (phases I to IV and observational). Survival-related variables were analyzed using decision tree algorithms, a machine learning method suited for revealing complex, non-linear patterns among clinical features. The models stratified patients based on baseline characteristics and treatment outcomes. The results revealed distinct predictive profiles for each cancer type. In head and neck cancer, survival was best predicted by race, disease status, use of radiotherapy, performance status, and toxic habits. In brain tumors, the most influential variables were age, performance status, and histological subtype. In esophageal cancer, survival was mainly determined by sex, histological diagnosis, and race. These variables consistently emerged as key decision nodes in the trained models. The novelty of this study lies in its use of a machine learning approach across multiple tumor types treated with the same targeted therapy, Nimotuzumab. It is also among the first to apply such methodology to real-world data from low- and middle-income countries. By generating interpretable decision trees, the study offers a practical tool for identifying patient subgroups that are most likely to benefit from EGFR-targeted treatment, thereby supporting more efficient, personalized cancer care. These findings reinforce the value of integrating data mining and artificial intelligence techniques into oncology to enhance treatment selection and improve patient outcomes.
- Open Access
- 6 May 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (5) , 1122
Treatment of Advanced NSCLC Patients with an Anti-Idiotypic NeuGcGM3-Based Vaccine: Immune Correlates in Long-Term Survivors
Background: Racotumomab-alum is an anti-idiotype vaccine targeting the NeuGcGM3 tumor-associated ganglioside. Clinical trials in advanced cancer patients have demonstrated low toxicity, high immunogenicity and clinical benefit. The goal of this study was to identify circulating biomarkers of clinical outcome. Methods: Eighteen patients with stage IIIb/IV non-small-cell lung cancer (NSCLC) were injected with racotumomab-alum as switch maintenance therapy after first-line chemotherapy. Treatment was administered until severe performance status worsening or toxicity. The frequencies of innate and adaptive lymphocytes were assessed by flow cytometry. Circulating factors were measured using multi-analyte flow assay kits. Results: The median overall survival was 16.5 months. Twenty-seven percent of patients were classified as long-term survivors. Patients with lower baseline frequencies of CD4+Tregs and central memory (CM) CD8+T cells displayed longer survival rates. Furthermore, higher baseline frequencies of NKT cells and a high CD8+T/CD4+Treg ratio were associated with longer survival. Interestingly, patients with significantly lower levels of effector memory (EM) CD8+T cells survived longer. The levels of NKT cells and terminal effector memory (EMRA) CD8+T cells were higher in long-term survivors in comparison with short-term survivors in post-immune samples. As expected, the ratio of CD8+T/CD4+Tregs showed significantly higher values during treatment in patients with clinical benefits. Regarding serum factors, pro-tumorigenic cytokines significantly increased during treatment in poor survivors. Conclusions: In advanced NSCLC patients receiving racotumomab-alum vaccine, longer survival could be associated with a unique profile of circulating lymphocyte subsets at baseline and during treatment. Additionally, certain pro-tumor-related cytokines increased in short-term survivors. These results should be confirmed in larger randomized clinical trials. This clinical trial was registered in the Cuban Clinical Trials Register (RPCE00000279).
- 6 May 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (5) , 1122
Open AccessTreatment of Advanced NSCLC Patients with an Anti-Idiotypic NeuGcGM3-Based Vaccine: Immune Correlates in Long-Term Survivors
Background: Racotumomab-alum is an anti-idiotype vaccine targeting the NeuGcGM3 tumor-associated ganglioside. Clinical trials in advanced cancer patients have demonstrated low toxicity, high immunogenicity and clinical benefit. The goal of this study was to identify circulating biomarkers of clinical outcome. Methods: Eighteen patients with stage IIIb/IV non-small-cell lung cancer (NSCLC) were injected with racotumomab-alum as switch maintenance therapy after first-line chemotherapy. Treatment was administered until severe performance status worsening or toxicity. The frequencies of innate and adaptive lymphocytes were assessed by flow cytometry. Circulating factors were measured using multi-analyte flow assay kits. Results: The median overall survival was 16.5 months. Twenty-seven percent of patients were classified as long-term survivors. Patients with lower baseline frequencies of CD4+Tregs and central memory (CM) CD8+T cells displayed longer survival rates. Furthermore, higher baseline frequencies of NKT cells and a high CD8+T/CD4+Treg ratio were associated with longer survival. Interestingly, patients with significantly lower levels of effector memory (EM) CD8+T cells survived longer. The levels of NKT cells and terminal effector memory (EMRA) CD8+T cells were higher in long-term survivors in comparison with short-term survivors in post-immune samples. As expected, the ratio of CD8+T/CD4+Tregs showed significantly higher values during treatment in patients with clinical benefits. Regarding serum factors, pro-tumorigenic cytokines significantly increased during treatment in poor survivors. Conclusions: In advanced NSCLC patients receiving racotumomab-alum vaccine, longer survival could be associated with a unique profile of circulating lymphocyte subsets at baseline and during treatment. Additionally, certain pro-tumor-related cytokines increased in short-term survivors. These results should be confirmed in larger randomized clinical trials. This clinical trial was registered in the Cuban Clinical Trials Register (RPCE00000279).
- Open Access
- 21 February 2025
- Published by MDPI AG in Preprints.org
Treatment of Advanced NSCLC Patients with an Anti-Idiotypic NeuGcGM3-Based Vaccine: Immune Correlates in Long-Term Survivors
Background: Racotumomab-alum is an anti-idiotype vaccine targeting the NeuGcGM3 tumor-associated ganglioside. Clinical trials in advanced cancer patients have demonstrated low toxicity, high immunogenicity and clinical benefit. The goal of this study was to identify circulating biomarkers of clinical outcome. Methods: Eighteen patients with stage IIIb/IV non-small-cell lung cancer (NSCLC) were injected with racotumomab-alum as switch maintenance therapy after first line chemotherapy. Treatment was administered until severe performance status worsening or toxicity. The frequencies of innate and adaptive lymphocytes were assessed by flow cytometry. Circulat ing factors were measured using multi-analyte flow assay kits. Results: The median overall survival was 16.5 months. Twenty-seven percent of patients were classified as long-term survivors. Patients with lower baseline frequencies of CD4+Tregs and central memory (CM) CD8+T cells displayed longer survival rates. Furthermore, higher baseline frequencies of NKT cells and a high CD8+T/CD4+Treg ratio were associated with longer survival. Interestingly, patients with significantly lower levels of effector memory (EM) CD8+T cells survived longer. The levels of NKT cells and terminal effector memory (EMRA) CD8+T cells were higher in long–term survivors in comparison with short-term survivors at post-immune samples. As expected, the ratio CD8+T/CD4+Tregs showed significantly higher values during treatment in patients with clinical benefits. Regarding serum factors, pro-tumorigenic cytokines significantly increased during treatment in poor survivors. Conclusions: In advanced NSCLC patients receiving racotumomab-alum vaccine, longer survival is associated with a unique profile of circulating lymphocyte subsets at baseline and during treatment. Additionally, certain protumor-related cytokines increased in short-term survivors. These results should be confirmed in larger clinical trials. This clinical trial was registered in Cuban Clinical Trials Register (RPCE00000279).
- 21 February 2025
- Published by MDPI AG in Preprints.org
Open AccessTreatment of Advanced NSCLC Patients with an Anti-Idiotypic NeuGcGM3-Based Vaccine: Immune Correlates in Long-Term Survivors
Background: Racotumomab-alum is an anti-idiotype vaccine targeting the NeuGcGM3 tumor-associated ganglioside. Clinical trials in advanced cancer patients have demonstrated low toxicity, high immunogenicity and clinical benefit. The goal of this study was to identify circulating biomarkers of clinical outcome. Methods: Eighteen patients with stage IIIb/IV non-small-cell lung cancer (NSCLC) were injected with racotumomab-alum as switch maintenance therapy after first line chemotherapy. Treatment was administered until severe performance status worsening or toxicity. The frequencies of innate and adaptive lymphocytes were assessed by flow cytometry. Circulat ing factors were measured using multi-analyte flow assay kits. Results: The median overall survival was 16.5 months. Twenty-seven percent of patients were classified as long-term survivors. Patients with lower baseline frequencies of CD4+Tregs and central memory (CM) CD8+T cells displayed longer survival rates. Furthermore, higher baseline frequencies of NKT cells and a high CD8+T/CD4+Treg ratio were associated with longer survival. Interestingly, patients with significantly lower levels of effector memory (EM) CD8+T cells survived longer. The levels of NKT cells and terminal effector memory (EMRA) CD8+T cells were higher in long–term survivors in comparison with short-term survivors at post-immune samples. As expected, the ratio CD8+T/CD4+Tregs showed significantly higher values during treatment in patients with clinical benefits. Regarding serum factors, pro-tumorigenic cytokines significantly increased during treatment in poor survivors. Conclusions: In advanced NSCLC patients receiving racotumomab-alum vaccine, longer survival is associated with a unique profile of circulating lymphocyte subsets at baseline and during treatment. Additionally, certain protumor-related cytokines increased in short-term survivors. These results should be confirmed in larger clinical trials. This clinical trial was registered in Cuban Clinical Trials Register (RPCE00000279).
- Open Access
- 15 December 2024
- Published by Clinical Biotec S.L. in Bionatura Journal
- Vol. 1 (4) , 13
Nimotuzumab and CIMAvax-EGF® in Advanced Cervical Cancer
Cervical cancer is the fourth cancer worldwide in the female sex in terms of incidence, becoming one of the most frequent epithelial tumors. The high overexpression of the Epidermal Growth Factor Receptor (EGFr) present in it offers the opportunity to use therapies against this receptor. A prospective, multicenter Expanded Access Program (EAP) was carried out in three randomized groups to demonstrate the safety and preliminary efficacy of humanized monoclonal antibody nimotuzumab, CIMAvax-EGF® vaccine and its combination in advanced cervical cancer, refractory to all previous oncospecific therapies. The principal endpoint was to assess overall survival time (the life expectancy of these patients at the inclusion was six months) and demonstrate the safety of those treatments. Overall survival was higher than expected in all groups. In general, 43.9% of patients were alive 2 years after the start of immunotherapy, and the 60-month survival rate was 38.8, 42.7, and 37.4% for CIMAvax-EGF®, Nimotuzumab, and combination therapies, respectively. According to overall survival, patients were separated into two groups: long (upper 24 months) and short (24 months or less) survivors. Long survivors (LS) represent 37.7% in the CIMAvax-EGF® vaccine, 49.3% in the Nimotuzumab, and 43.5% in the combination group. Adenocarcinomas (ADCs) tumors benefited from vaccine therapy, and squamous cell carcinomas with a nimotuzumab also benefited. A combination of both does not improve survival more than monotherapy. Nimotuzumab and CIMAvax-EGF® become an opportunity to treat refractory advanced cervical cancer.
- 15 December 2024
- Published by Clinical Biotec S.L. in Bionatura Journal
- Vol. 1 (4) , 13
Open AccessNimotuzumab and CIMAvax-EGF® in Advanced Cervical Cancer
Cervical cancer is the fourth cancer worldwide in the female sex in terms of incidence, becoming one of the most frequent epithelial tumors. The high overexpression of the Epidermal Growth Factor Receptor (EGFr) present in it offers the opportunity to use therapies against this receptor. A prospective, multicenter Expanded Access Program (EAP) was carried out in three randomized groups to demonstrate the safety and preliminary efficacy of humanized monoclonal antibody nimotuzumab, CIMAvax-EGF® vaccine and its combination in advanced cervical cancer, refractory to all previous oncospecific therapies. The principal endpoint was to assess overall survival time (the life expectancy of these patients at the inclusion was six months) and demonstrate the safety of those treatments. Overall survival was higher than expected in all groups. In general, 43.9% of patients were alive 2 years after the start of immunotherapy, and the 60-month survival rate was 38.8, 42.7, and 37.4% for CIMAvax-EGF®, Nimotuzumab, and combination therapies, respectively. According to overall survival, patients were separated into two groups: long (upper 24 months) and short (24 months or less) survivors. Long survivors (LS) represent 37.7% in the CIMAvax-EGF® vaccine, 49.3% in the Nimotuzumab, and 43.5% in the combination group. Adenocarcinomas (ADCs) tumors benefited from vaccine therapy, and squamous cell carcinomas with a nimotuzumab also benefited. A combination of both does not improve survival more than monotherapy. Nimotuzumab and CIMAvax-EGF® become an opportunity to treat refractory advanced cervical cancer.
- Open Access
- 15 December 2024
- Published by Clinical Biotec S.L. in Bionatura Journal
- Vol. 1 (4) , 11
Treatment of progressive ovarian tumors with the therapeutic combination of the AcM Nimotuzumab and the NGGM3/VSSP vaccine
Ovarian cancer ranks third among gynecological cancers and accounts for 4% of cancers in women. Antitumor immunotherapies constitute new therapeutic tools for identifying molecules differentially expressed in tumor cells. An exploratory study evaluated the safety and efficacy of a vaccine preparation containing NGlicolilGM3 (NGGM3/VSSP) and the Monoclonal Antibody Nimotuzumab (AcM CIMAher). Both products have proven to be safe and can be applied in combination with chemotherapy (QTP). Survival (OS) in patients who received QTP, AcM Nimotuzumab, and the NGGM3/VSSP vaccine was superior to those who did not receive chemotherapy. The antitumor effect of the combination may be synergistic since the therapies are directed at two tumor targets and act through different mechanisms.
- 15 December 2024
- Published by Clinical Biotec S.L. in Bionatura Journal
- Vol. 1 (4) , 11
Open AccessTreatment of progressive ovarian tumors with the therapeutic combination of the AcM Nimotuzumab and the NGGM3/VSSP vaccine
Ovarian cancer ranks third among gynecological cancers and accounts for 4% of cancers in women. Antitumor immunotherapies constitute new therapeutic tools for identifying molecules differentially expressed in tumor cells. An exploratory study evaluated the safety and efficacy of a vaccine preparation containing NGlicolilGM3 (NGGM3/VSSP) and the Monoclonal Antibody Nimotuzumab (AcM CIMAher). Both products have proven to be safe and can be applied in combination with chemotherapy (QTP). Survival (OS) in patients who received QTP, AcM Nimotuzumab, and the NGGM3/VSSP vaccine was superior to those who did not receive chemotherapy. The antitumor effect of the combination may be synergistic since the therapies are directed at two tumor targets and act through different mechanisms.
- Open Access
- 1 June 2021
- Published by Taylor & Francis in International Journal of Women's Health
- Vol. ume 13, 569-577
Reliability and Dimensionality of EPREVO (“Experiencias de Parto Relacionadas a Violencia Obstétrica”): Development of a New Instrument, Ecuador
Background: A new instrument called EPREVO has been developed to measure obstetric violence in Ecuador and the objective of this work is to validate its reliability and structural dimensionality. Methods: Using confirmatory factor analysis (CFA) with a tetrachoric correlation approach. We examined the factor structure of EPREVO, a Spanish instrument to measure obstetric violence. Kuder Richardson values were used to assess the internal consistency of the scale and dimensionality was confirmed with confirmatory factor analysis. Results: Confirmatory factor analysis supported a 3-factor solution. Most item-to-factor-correlations presented moderate to strong magnitude. Total Kuder Richardson was 0.87, while for the three factors were 0.23, 0.47 and 0.94, respectively. The model’s goodness-of-fit indexes were satisfactory (χ 2 = 1458.83; χ 2/g.l = 2.60, p < 0.001; NNFI = 0.90; RMSEA = 0.09); most of the factor loads were greater than 0.30. A confirmatory factor analysis suggested a 3-dimensional structure of EPREVO. Conclusion: The scale’s factor structure presented satisfactory validity and reliability results, except for one factor. The 30 items scale could potentially be used as an instrument for assessing obstetric violence in different healthcare settings.
- 1 June 2021
- Published by Taylor & Francis in International Journal of Women's Health
- Vol. ume 13, 569-577
Open AccessReliability and Dimensionality of EPREVO (“Experiencias de Parto Relacionadas a Violencia Obstétrica”): Development of a New Instrument, Ecuador
Background: A new instrument called EPREVO has been developed to measure obstetric violence in Ecuador and the objective of this work is to validate its reliability and structural dimensionality. Methods: Using confirmatory factor analysis (CFA) with a tetrachoric correlation approach. We examined the factor structure of EPREVO, a Spanish instrument to measure obstetric violence. Kuder Richardson values were used to assess the internal consistency of the scale and dimensionality was confirmed with confirmatory factor analysis. Results: Confirmatory factor analysis supported a 3-factor solution. Most item-to-factor-correlations presented moderate to strong magnitude. Total Kuder Richardson was 0.87, while for the three factors were 0.23, 0.47 and 0.94, respectively. The model’s goodness-of-fit indexes were satisfactory (χ 2 = 1458.83; χ 2/g.l = 2.60, p < 0.001; NNFI = 0.90; RMSEA = 0.09); most of the factor loads were greater than 0.30. A confirmatory factor analysis suggested a 3-dimensional structure of EPREVO. Conclusion: The scale’s factor structure presented satisfactory validity and reliability results, except for one factor. The 30 items scale could potentially be used as an instrument for assessing obstetric violence in different healthcare settings.
- 2 November 2020
- Published by Springer Nature in Quality of Life Research
- Vol. 29 (12) , 3441-3448
Underlying dimensions of the EORTC QLQ-C30 in a Cuban population of patients with advanced non-small cell lung cancer
Background Quality of Life Core Questionnaire of the European Organization for the Research and Treatment of Cancer (EORTC QLQ-C30) is one of the most used quality of life questionnaires in cancer studies. It provides scores for five functional scales, nine symptom scales, and two single items which assess overall health status and quality of life. However, high correlations among QLQ-C30 items suggest a reduced dimensionality for the scale. Objective To assess the dimensionality of the EORTC QLQ-C30 using item response theory (IRT) in a training sample and confirmatory factor analysis (CFA) in a test sample. Methods We analyzed responses to QLQ-C30 from 1,107 patients with advanced lung cancer who were included in five clinical trials of immunotherapy. We used non-parametric and parametric IRT models (Mokken, and Samejima's graded response) in a random training set (n = 332) for initial assessment of dimensions and item characteristics of the QLQ-C30. Finally, we used CFA in the test set (n = 775) to confirm the measurement domains. Results Mokken model showed that QLQ-C30 fits a unidimensional scale, whereas Samejima model showed that most QLQ-C30 items present adequate difficulty and discrimination. All items showed adequate scalability indexes with an overall scalability of 0.47 (medium scale). The QLQ-C30-reduced dimensionality was confirmed by CFA (comparative fit index = 0.98, root mean square error of approximation = 0.055) with all items presenting factorial loadings > 0.40. Conclusions The EORTC QLQ-C30 fits a unidimensional latent construct identified with perceived quality of life in advanced lung cancer patients. Trial registration RPCEC00000161, RPCEC00000181 and RPCEC00000205
- 2 November 2020
- Published by Springer Nature in Quality of Life Research
- Vol. 29 (12) , 3441-3448
Underlying dimensions of the EORTC QLQ-C30 in a Cuban population of patients with advanced non-small cell lung cancer
Background Quality of Life Core Questionnaire of the European Organization for the Research and Treatment of Cancer (EORTC QLQ-C30) is one of the most used quality of life questionnaires in cancer studies. It provides scores for five functional scales, nine symptom scales, and two single items which assess overall health status and quality of life. However, high correlations among QLQ-C30 items suggest a reduced dimensionality for the scale. Objective To assess the dimensionality of the EORTC QLQ-C30 using item response theory (IRT) in a training sample and confirmatory factor analysis (CFA) in a test sample. Methods We analyzed responses to QLQ-C30 from 1,107 patients with advanced lung cancer who were included in five clinical trials of immunotherapy. We used non-parametric and parametric IRT models (Mokken, and Samejima's graded response) in a random training set (n = 332) for initial assessment of dimensions and item characteristics of the QLQ-C30. Finally, we used CFA in the test set (n = 775) to confirm the measurement domains. Results Mokken model showed that QLQ-C30 fits a unidimensional scale, whereas Samejima model showed that most QLQ-C30 items present adequate difficulty and discrimination. All items showed adequate scalability indexes with an overall scalability of 0.47 (medium scale). The QLQ-C30-reduced dimensionality was confirmed by CFA (comparative fit index = 0.98, root mean square error of approximation = 0.055) with all items presenting factorial loadings > 0.40. Conclusions The EORTC QLQ-C30 fits a unidimensional latent construct identified with perceived quality of life in advanced lung cancer patients. Trial registration RPCEC00000161, RPCEC00000181 and RPCEC00000205